## Eboni I Lance

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1116629/publications.pdf

Version: 2024-02-01

1478505 996975 25 226 15 6 citations h-index g-index papers 25 25 25 292 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Aspirin Use in Sturge-Weber Syndrome. Journal of Child Neurology, 2013, 28, 213-218.	1.4	100
2	Stimulant Use in Patients With Sturge-Weber Syndrome: Safety and Efficacy. Pediatric Neurology, 2014, 51, 675-680.	2.1	18
3	Risk Factors for Attention and Behavioral Issues in Pediatric Sickle Cell Disease. Clinical Pediatrics, 2015, 54, 1087-1093.	0.8	15
4	Association between regression and self injury among children with autism. Research in Developmental Disabilities, 2014, 35, 408-413.	2.2	14
5	Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease. Proteomics - Clinical Applications, 2014, 8, 813-827.	1.6	14
6	Expansion of the Deletion 13q Syndrome Phenotype: A Case Report. Journal of Child Neurology, 2007, 22, 1124-1127.	1.4	10
7	Co-Occurrence of Neurodevelopmental Disorders in Pediatric Sickle Cell Disease. Journal of Developmental and Behavioral Pediatrics, 2021, 42, 463-471.	1.1	8
8	The Montreal cognitive assessment as a cognitive screening tool in sickle cell disease: Associations with clinically significant cognitive domains. British Journal of Haematology, 2022, , .	2.5	7
9	Disparities in Identification of Comorbid Diagnoses in Children With ADHD. Clinical Pediatrics, 2015, 54, 376-381.	0.8	6
10	Imaging Blood–Brain Barrier Permeability Through <scp>MRI</scp> in Pediatric Sickle Cell Disease: A Feasibility Study. Journal of Magnetic Resonance Imaging, 2022, 55, 1551-1558.	3.4	6
11	Confounding Diagnoses in the Neurodevelopmental Disabilities Population. Journal of Child Neurology, 2013, 28, 645-647.	1.4	5
12	Successful treatment of choreo-athetotic movements in a patient with an EEF1A2 gene variant. SAGE Open Medical Case Reports, 2018, 6, 2050313X1880762.	0.3	5
13	Brainâ€derived neurotrophic factor levels in pediatric sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28076.	1.5	5
14	Perspective: Sistas In Science – Cracking the Glass Ceiling. Ethnicity and Disease, 2018, 28, 575-578.	2.3	3
15	Evaluation of Macular Flow Voids on Optical Coherence Tomography Angiography [OCT-A] as Potential Biomarkers for Silent Cerebral Infarction in Sickle Cell Disease. Retina, 2021, Publish Ahead of Print, .	1.7	3
16	Brain Oxygen Extraction and Metabolism in Pediatric Patients With Sickle Cell Disease: Comparison of Four Calibration Models. Frontiers in Physiology, 2022, 13, 814979.	2.8	3
17	Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease. Proteomics - Clinical Applications, 2021, 15, 2100003.	1.6	2
18	Sickle Cell Anemia. , 2017, , .		1

## EBONI I LANCE

#	Article	IF	Citations
19	Neurodevelopmental Screening in Young Children with Sickle Cell Disease. Blood, 2021, 138, 2050-2050.	1.4	1
20	Hydroxycarbamide and white matter integrity in paediatric sickle cell disease. British Journal of Haematology, $2019,  ,  .$	2.5	0
21	Hydroxycarbamide and white matter integrity in pediatric sickle cell disease. British Journal of Haematology, 2019, 187, 141-143.	2.5	O
22	Patients with Sickle Cell Disease and Autism Spectrum Disorder. Advances in Neurodevelopmental Disorders, 2021, 5, 457.	1.1	0
23	Sickle Cell Disease and Vestibular Dysfunction. Blood, 2021, 138, 4183-4183.	1.4	O
24	Functional Connectivity in Pediatric Sickle Cell Disease. Blood, 2021, 138, 2049-2049.	1.4	0
25	Neurocognitive screening in sickle cell disease. Pediatric Blood and Cancer, 2022, 69, .	1.5	0